Mitochondrial DNA-triggered innate immune response: mechanisms and diseases
Various cellular stress conditions trigger mitochondrial DNA (mtDNA) release from mitochondria into the cytosol. The released mtDNA is sensed by the cGAS-MITA/STING pathway, resulting in the induced expression of type I interferon and other effector genes. These processes contribute to the innate immune response to viral infection and other stress factors. The deregulation of these processes causes autoimmune diseases, inflammatory metabolic disorders and cancer. Therefore, the cGAS-MITA/STING pathway is a potential target for intervention in infectious, inflammatory and autoimmune diseases as well as cancer. In this review, we focus on the mechanisms underlying the mtDNA-triggered activation of the cGAS-MITA/STING pathway, the effects of the pathway under various physiological and pathological conditions, and advances in the development of drugs that target cGAS and MITA/STING.
Top-30
Journals
|
1
2
3
4
5
6
7
|
|
|
Frontiers in Immunology
7 publications, 6.36%
|
|
|
Advanced Science
4 publications, 3.64%
|
|
|
International Immunopharmacology
4 publications, 3.64%
|
|
|
Viruses
3 publications, 2.73%
|
|
|
International Journal of Molecular Sciences
3 publications, 2.73%
|
|
|
Journal of Nanobiotechnology
3 publications, 2.73%
|
|
|
Journal of Translational Medicine
3 publications, 2.73%
|
|
|
Biomolecules
2 publications, 1.82%
|
|
|
Phytomedicine
2 publications, 1.82%
|
|
|
Food and Chemical Toxicology
2 publications, 1.82%
|
|
|
Mitochondrion
2 publications, 1.82%
|
|
|
Bioactive Materials
2 publications, 1.82%
|
|
|
Biomedicines
2 publications, 1.82%
|
|
|
Signal Transduction and Targeted Therapy
2 publications, 1.82%
|
|
|
MedComm
2 publications, 1.82%
|
|
|
Advanced Materials
2 publications, 1.82%
|
|
|
Nature Communications
2 publications, 1.82%
|
|
|
Cell Death and Disease
1 publication, 0.91%
|
|
|
Pathology Research and Practice
1 publication, 0.91%
|
|
|
Biomedicine and Pharmacotherapy
1 publication, 0.91%
|
|
|
European Journal of Medicinal Chemistry
1 publication, 0.91%
|
|
|
Comparative Immunology Reports
1 publication, 0.91%
|
|
|
Best Practice and Research in Clinical Rheumatology
1 publication, 0.91%
|
|
|
Experimental Neurology
1 publication, 0.91%
|
|
|
Journal of Translational Autoimmunity
1 publication, 0.91%
|
|
|
npj Viruses
1 publication, 0.91%
|
|
|
Cellular and Molecular Neurobiology
1 publication, 0.91%
|
|
|
bioRxiv
1 publication, 0.91%
|
|
|
Neurobiology of Disease
1 publication, 0.91%
|
|
|
1
2
3
4
5
6
7
|
Publishers
|
5
10
15
20
25
30
35
40
|
|
|
Elsevier
37 publications, 33.64%
|
|
|
Springer Nature
23 publications, 20.91%
|
|
|
MDPI
12 publications, 10.91%
|
|
|
Wiley
12 publications, 10.91%
|
|
|
Frontiers Media S.A.
8 publications, 7.27%
|
|
|
Cold Spring Harbor Laboratory
6 publications, 5.45%
|
|
|
Oxford University Press
2 publications, 1.82%
|
|
|
Taylor & Francis
2 publications, 1.82%
|
|
|
American Association for the Advancement of Science (AAAS)
1 publication, 0.91%
|
|
|
BMJ
1 publication, 0.91%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
1 publication, 0.91%
|
|
|
OAE Publishing Inc.
1 publication, 0.91%
|
|
|
Bentham Science Publishers Ltd.
1 publication, 0.91%
|
|
|
Royal Society of Chemistry (RSC)
1 publication, 0.91%
|
|
|
American Society for Microbiology
1 publication, 0.91%
|
|
|
American Chemical Society (ACS)
1 publication, 0.91%
|
|
|
5
10
15
20
25
30
35
40
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.